TMCnet News
Research and Markets: Global Non-Small Cell Lung Cancer Market to 2020: Pipeline Entries to Drive NSCLC Market GrowthDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/dtpwk2/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market" report to their offering. The Non-Small Cell Lung Cancer (NSCLC) market will undergo considerable growth from $5.1 billion in 2013 to $7.9 billion in 2020 at a Compound Annual Growth Rate (CAGR) of 6.6%. The added value will be derived from an abundance of new product launches relatively early in the forecast period. Many of these therapies will target the second line of treatment; both the first-line treatment of patients with non-squamous histology and the maintenance setting will remain relatively unchanged by 2020. New second-line therapies include immunostimulants such as ramucirumab and nivolumab, which have shown clinical benefits, but which will face difficulties due to the increasingly crowded second-line setting. Currently, pharmaceutical treatment is limited to late-stage patients. However, vaccine therapies such as Lucanix (belagenpumatucel-L) will launch in the forecast period, for patients with stage II or IIIA NSCLC, in the currently sparse adjuvant setting. Although vaccine treatments have been unsuccessful so far in NSCLC - the most recent example being GSK's MAGE-A3 vaccine failing its Phase III trial - Lucanix has shownlarge improvements to survival rates in its initial clinical trials. Monoclonal Antibodies to Diversify Squamous Cell Treatment Over the forecast period to 2020, several new additions to the NSCLC treatment paradigm will transform the treatment landscape. Many of these will be monoclonal Antibodies (mAbs), which instigate an immune response to the tumor rather than directly affecting cancer cells. Crucially, some of these mAbs will be indicated for patients with squamous cell histology, whose current treatment options are very limited and primarily consist of chemotherapy. Squamous cell histology accounts for approximately 30% of the NSCLC population, and pipeline products, such as Yervoy (ipilimumab) in the first-line treatment and nivolumab in the second-line, will add greater diversity to the treatment algorithm, with both having shown clinical benefits in early-stage trials. Access to these premium treatments in this under-represented segment will be one of the primary drivers for growth in the overall NSCLC market. Efforts are being made to understand the molecular characterization of NSCLC tumors in order to identify cancer-cell-specific targets for therapy, based on the success of targeted therapies Tarceva (erlotinib) and Xalkori (crizotinib). However, novel therapies targeting these molecules, such as Kirsten Rat Sarcoma viral oncogene homolog (KRAS), have so far been unsuccessful in the late-stage pipeline, meaning that the range of mutant signal pathway molecules targeted by therapy will remain largely unchanged over the forecast period and mAb immunotherapies targeting cancer or T-cell antigens will have a much larger impact than small-molecule-targeted signal inhibitors. Key Topics Covered: 1 Tables & Figures 2 Introduction
3 Marketed Products
4 NSCLC Pipeline
5 Market Forecast
6 Strategic Consolidations
7 Appendix For more information visit http://www.researchandmarkets.com/research/dtpwk2/nonsmall_cell
|
